user

Phase I dose escalation study of E7080, a novel anti-angiogenic multikinase inhibitor, in Japanese patients with advanced solid tumors

被引：0
|
作者：
Yamada, K. [1 ]
Fujiwara, Y. [1 ]
Yamamoto, N. [1 ]
Yamada, Y. [1 ]
Suzuki, S. [1 ]
Kobayashi, N. [1 ]
Koizumi, F. [1 ]
Nishio, K. [1 ]
Tamura, T. [1 ]
机构：
[1] Natl Canc Ctr, Tokyo, Japan
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2007年 / 25卷 / 18期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
14099
引用
下载
收藏
页数：1
相关论文
共 50 条
  • [41] A phase I dose-escalation study of the novel gamma secretase inhibitor PF-03084014 in patients (pts) with advanced solid tumors.
    Messersmith, W. A.
    LoRusso, P.
    Cleary, J. M.
    Dasari, A.
    Zhang, X.
    Shaik, M. N.
    Courtney, R. D.
    Randolph, S.
    Shapiro, G.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [42] Phase I Dose Escalation and Pharmacokinetic Study of BI 2536, a Novel Polo-Like Kinase 1 Inhibitor, in Patients With Advanced Solid Tumors
    Mross, Klaus
    Frost, Annette
    Steinbild, Simone
    Hedbom, Susanne
    Rentschler, Jochen
    Kaiser, Rolf
    Rouyrre, Nicolas
    Trommeshauser, Dirk
    Hoesl, Cornelia E.
    Munzert, Gerd
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (34) : 5511 - 5517
  • [43] Phase I Dose-Escalation Study of LCL161, an Oral Inhibitor of Apoptosis Proteins Inhibitor, in Patients With Advanced Solid Tumors
    Infante, Jeffrey R.
    Dees, E. Claire
    Olszanski, Anthony J.
    Dhuria, Shyeilla V.
    Sen, Suman
    Cameron, Scott
    Cohen, Roger B.
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (28) : 3103 - +
  • [44] Phase I dose escalation and pharmacokinetic study of oral enzastaurin in Japanese patients with advanced solid tumour
    Mukohara, T.
    Nagai, S.
    Nambu, Y.
    Yoshizawa, K.
    Minami, H.
    EJC SUPPLEMENTS, 2008, 6 (12): : 132 - 132
  • [45] Phase I trial of fruquintinib in patients with advanced solid tumors; Results of the dose escalation phase
    Wang-Gillam, A.
    Yeckes-Rodin, H.
    Kosmo, M. A.
    Stanton, T.
    Park, H.
    Songhua, F.
    Sauter, N. P.
    Kania, M.
    ANNALS OF ONCOLOGY, 2019, 30 : 175 - +
  • [46] A phase I dose escalation study of TTI-237 in patients with advanced malignant solid tumors
    Andrea Wang-Gillam
    Susanne M. Arnold
    Ronald M. Bukowski
    Mace L. Rothenberg
    Wendy Cooper
    Kenneth K. Wang
    Eric Gauthier
    A. Craig Lockhart
    Investigational New Drugs, 2012, 30 : 266 - 272
  • [47] A phase I dose-escalation and pharmacokinetic study of enzastaurin and erlotinib in patients with advanced solid tumors
    Padda, Sukhmani K.
    Krupitskaya, Yelena
    Chhatwani, Laveena
    Fisher, George A.
    Colevas, Alexander D.
    Pedro-Salcedo, Melanie San
    Decker, Rodney
    Latz, Jane E.
    Wakelee, Heather A.
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2012, 69 (04) : 1013 - 1020
  • [48] Phase I/Ib dose-escalation study of aveluma in Chinese patients with advanced solid tumors
    Wu, Yi-Long
    Cheng, Ying
    Chen, Huajun
    Tu, Haiyan
    Xu, Chongrui
    Wang, Zhen
    Liu, Ying
    Xin, Ying
    Lou, Haizhou
    Wang, Wei
    Chin, Kevin
    Li, Dandan
    Zhao, Di
    Gao, Yanfei
    Xu, Wenping
    Pan, Hongming
    FUTURE ONCOLOGY, 2022,
  • [49] A Phase I dose-escalation study of afatinib combined with nintedanib in patients with advanced solid tumors
    Gordon, Michael S.
    Springett, Gregory M.
    Su, Yungpo Bernard
    Ould-Kaci, Mahmoud
    Wind, Sven
    Zhao, Yihua
    LoRusso, Patricia M.
    FUTURE ONCOLOGY, 2015, 11 (10) : 1479 - 1491
  • [50] A phase I dose escalation study of TTI-237 in patients with advanced malignant solid tumors
    Wang-Gillam, Andrea
    Arnold, Susanne M.
    Bukowski, Ronald M.
    Rothenberg, Mace L.
    Cooper, Wendy
    Wang, Kenneth K.
    Gauthier, Eric
    Lockhart, A. Craig
    INVESTIGATIONAL NEW DRUGS, 2012, 30 (01) : 266 - 272
12345